Global Creative Marketing Agency with Tier-One Entertainment & Pharma Clients
Looking for more agencies like this?
Post a public acquisition mandate and get matched with agencies that fit your brief — daily.
Create your mandate$30.0M
$20.0M
$4.2M
7x
2003
100% B2B / 0% B2C
An award-winning, independent creative marketing agency operating across the UK, US, and LATAM, specialising in entertainment, gaming, and pharmaceutical communications. The business delivers culturally led, insight-driven campaigns across social, digital, PR, experiential, and paid media for globally recognised brands. The agency has a long-standing heritage in entertainment marketing alongside a differentiated and rapidly expanding pharmaceutical capability. By combining storytelling expertise with data, performance marketing, and compliance discipline, it executes high-impact global campaigns from strategic planning through to activation. Following a strategic realignment during 2023–2024, including a streamlined cost base and operational restructuring, the business is now positioned for accelerated growth. Revenue is expected to scale materially from 2025 onwards, driven by newly onboarded global media clients and the addition of a major multinational pharmaceutical client. This opportunity is well suited to strategic acquirers or investors seeking a globally positioned creative agency with premium client relationships, diversified sector exposure, and strong forward growth momentum.
- Blue-chip global client portfolio, including leading studios, streaming platforms, and pharmaceutical companies
- Renowned for social-first, experiential, and culturally resonant campaigns
- Unique positioning at the intersection of entertainment storytelling and healthcare communications
- International delivery capability with teams operating across multiple continents
- Experienced senior leadership with deep sector expertise and long tenure
- High level of client retention through repeat and multi-year engagements
- Strong forward revenue visibility driven by new global media mandates
- Secured major multinational pharmaceutical client onboarding for 2026
- Lean operational structure enhancing margins from 2025 onward